Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.58 USD | -1.81% | -4.63% | -8.15% |
05-23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
05-23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.15% | 1.46B | |
+15.20% | 79.23B | |
+8.92% | 8.66B | |
+56.03% | 4.89B | |
-17.73% | 4.72B | |
+1.31% | 3.81B | |
+21.47% | 2.42B | |
-25.43% | 2.22B | |
+14.61% | 2.08B | |
-37.31% | 1.96B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals Reports Higher Q1 Earnings, Revenue; Affirms 2022 Revenue Guidance